---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-026971"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2025-09-09T23:59:59+00:00"
generated_at: "2026-05-17T07:19:24.531467+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# bioAffinity Technologies case study shows CyPath Lung detects cancer in ground-glass nodules

## Summary
- Case study: 66-year-old former smoker with 13mm ground-glass nodule; CyPath Lung returned 'likely malignant' result.
- Robotic bronchoscopy confirmed lung cancer after positive CyPath result; patient referred for surgical treatment.
- Current guidelines recommend 2-5 years watchful waiting; CyPath may reduce diagnostic delay and uncertainty.
- Company issued press release on September 9, 2025 highlighting real-world clinical utility of CyPath Lung.

## SEC filing metadata
- accession: 0001641172-25-026971
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2025-09-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000164117225026971/0001641172-25-026971-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000164117225026971/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-026971
- JSON: https://secwatch.observer/filing/0001641172-25-026971.json
- Plain text: https://secwatch.observer/filing/0001641172-25-026971.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.